Rockwell Medical Inc (NASDAQ: RMTI), a fully-integrated biopharmaceutical company, announced yesterday that it has named Stuart Paul as its new chief executive officer of the company, effective 4 September 2018.
Paul will also join the Rockwell Medical board of directors at that time.
From 2007 to 2013, Paul worked at Gambro AB. Following the sale of Gambro AB to Baxter International, he led the integration of the combined Baxter-Gambro Renal business in Latin America. After his time at Gambro AB, he was with Quest Diagnostics for several years where he led the turnaround of the company's USD1.4bn US East Region laboratories, patient services and commercial business. Most recently, he served as corporate officer and vice president of Abbott Laboratories, where he facilitated integration of the recent Alere Inc acquisition, while leading its largest global business unit with USD600m of revenues.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva